p53 governs an AT1 differentiation programme in lung cancer suppression

• Published in: Nature (London) 2023-07, Vol.619 (7971), p.851-859
• Main Authors: Kaiser, Alyssa M., Gatto, Alberto, Hanson, Kathryn J., Zhao, Richard L., Raj, Nitin, Ozawa, Michael G., Seoane, José A., Bieging-Rolett, Kathryn T., Wang, Mengxiong, Li, Irene, Trope, Winston L., Liou, Douglas Z., Shrager, Joseph B., Plevritis, Sylvia K., Newman, Aaron M., Van Rechem, Capucine, Attardi, Laura D.
• Format: Article
• Language: English
• Subjects: 13/1; 13/51; 14/63; 38/39; 45/15; 45/23; 45/91; 631/67/1244; 631/67/1612/1350; 64/110; 64/60; 96/106; Alleles; Alveolar Epithelial Cells - cytology; Alveolar Epithelial Cells - metabolism; Alveolar Epithelial Cells - pathology; Alveoli; Animals; Cell Differentiation; Cell Lineage; Cell Self Renewal; Chromatin Assembly and Disassembly; Chromatin remodeling; Differentiation (biology); Disease Progression; DNA - metabolism; Gene expression; Gene Expression Profiling; Gene sequencing; Homeostasis; Humanities and Social Sciences; Inactivation; Injuries; Lung - cytology; Lung - metabolism; Lung - pathology; Lung cancer; Lung diseases; Lung Injury - genetics; Lung Injury - metabolism; Lung Injury - pathology; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Lung Neoplasms - prevention & control; Mice; Mice, Knockout; multidisciplinary; Mutation; p53 Protein; Regeneration; Respiratory system; Science; Science (multidisciplinary); Transcriptomics; Tumor suppressor genes; Tumor Suppressor Protein p53 - deficiency; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism; Tumors
• ISSN: 0028-0836; 1476-4687; 1476-4687
• DOI: 10.1038/s41586-023-06253-8

Lung cancer is the leading cause of cancer deaths worldwide 1 . Mutations in the tumour suppressor gene TP53 occur in 50% of lung adenocarcinomas (LUADs) and are linked to poor prognosis 1 – 4 , but how p53 suppresses LUAD development remains enigmatic. We show here that p53 suppresses LUAD by governing cell state, specifically by promoting alveolar type 1 (AT1) differentiation. Using mice that express oncogenic Kras and null, wild-type or hypermorphic Trp53 alleles in alveolar type 2 (AT2) cells, we observed graded effects of p53 on LUAD initiation and progression. RNA sequencing and ATAC sequencing of LUAD cells uncovered a p53-induced AT1 differentiation programme during tumour suppression in vivo through direct DNA binding, chromatin remodelling and induction of genes characteristic of AT1 cells. Single-cell transcriptomics analyses revealed that during LUAD evolution, p53 promotes AT1 differentiation through action in a transitional cell state analogous to a transient intermediary seen during AT2-to-AT1 cell differentiation in alveolar injury repair. Notably, p53 inactivation results in the inappropriate persistence of these transitional cancer cells accompanied by upregulated growth signalling and divergence from lung lineage identity, characteristics associated with LUAD progression. Analysis of Trp53 wild-type and Trp53- null mice showed that p53 also directs alveolar regeneration after injury by regulating AT2 cell self-renewal and promoting transitional cell differentiation into AT1 cells. Collectively, these findings illuminate mechanisms of p53-mediated LUAD suppression, in which p53 governs alveolar differentiation, and suggest that tumour suppression reflects a fundamental role of p53 in orchestrating tissue repair after injury. p53 is shown to have a pivotal role in the differentiation of alveolar type 1 cells in cancer and alveolar repair after injury, and loss of this governance can promote diseases such as lung adenocarcinoma.